Wealth Effects LLC Sells 183 Shares of Danaher Co. (NYSE:DHR)

Wealth Effects LLC lessened its stake in Danaher Co. (NYSE:DHR) by 13.0% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 1,220 shares of the conglomerate’s stock after selling 183 shares during the period. Wealth Effects LLC’s holdings in Danaher were worth $280,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in DHR. Fort Pitt Capital Group LLC increased its position in Danaher by 3.2% during the 3rd quarter. Fort Pitt Capital Group LLC now owns 238,092 shares of the conglomerate’s stock valued at $66,194,000 after purchasing an additional 7,421 shares during the period. Good Life Advisors LLC bought a new position in Danaher during the third quarter worth $217,000. ORG Partners LLC lifted its holdings in Danaher by 1,212.8% in the fourth quarter. ORG Partners LLC now owns 2,770 shares of the conglomerate’s stock valued at $636,000 after buying an additional 2,559 shares during the period. Harvest Portfolios Group Inc. grew its holdings in Danaher by 1.2% during the 3rd quarter. Harvest Portfolios Group Inc. now owns 202,263 shares of the conglomerate’s stock worth $56,233,000 after acquiring an additional 2,465 shares during the period. Finally, Stifel Financial Corp raised its position in shares of Danaher by 1.3% in the 3rd quarter. Stifel Financial Corp now owns 847,348 shares of the conglomerate’s stock worth $235,583,000 after acquiring an additional 11,216 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. Barclays lowered their target price on Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a report on Wednesday, October 23rd. Evercore ISI raised their price target on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Wolfe Research raised shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price objective on the stock in a research report on Thursday, October 31st. Citigroup dropped their price target on Danaher from $305.00 to $285.00 and set a “buy” rating on the stock in a research note on Monday, January 6th. Finally, Guggenheim began coverage on Danaher in a report on Thursday, December 19th. They set a “buy” rating and a $275.00 price objective for the company. Six equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and an average target price of $285.55.

Danaher Price Performance

Shares of NYSE:DHR opened at $250.51 on Tuesday. Danaher Co. has a fifty-two week low of $225.42 and a fifty-two week high of $281.70. The company’s 50-day moving average is $235.33 and its 200 day moving average is $253.62. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. The company has a market capitalization of $180.94 billion, a P/E ratio of 47.81, a price-to-earnings-growth ratio of 4.43 and a beta of 0.83.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be issued a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.43%. The ex-dividend date is Friday, December 27th. Danaher’s dividend payout ratio (DPR) is presently 20.61%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.